연구동향 분석

그레이브스병에서 방사성요오드 치료의 최신지견

정신영 2019년

논문상세정보
인용/피인용
' 그레이브스병에서 방사성요오드 치료의 최신지견' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Graves’ disease
  • Radioactive iodine
  • hyperthyroidism
  • thyroid
  • 갑상선
  • 갑상선기능항진증
  • 그레이브스병
  • 방사성요오드
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
162 0

0.0%

' 그레이브스병에서 방사성요오드 치료의 최신지견' 의 참고문헌

  • 건강보험심사평가원 자료로 분석한 우리나라 갑상선기능항진증의 발생률/유병률 조사와 치료법 선호도의 분석
    서기현 [2013]
  • 갑상선기능항진증의 진단 및 치료- 대한갑상선학회 합의안
    이가희 [2013]
  • Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism
    Bartalena L [1989]
  • Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine
  • Thyroid function and mortality in patients treated for hyperthyroidism
    Franklyn JA [2005]
  • Thyroid disease and increased cardiovascular risk
    Nyirenda MJ [2005]
  • Therapeutic controversies. Summation, commentary, and overview: concerns over aggravation of Graves' ophthalmopathy by radioactive iodine treatment and the use of retrobulbar radiation therapy
    Wartofsky L [1995]
  • The management of hyperthyroidism
    Franklyn JA [1994]
  • TSH-receptor autoimmunity in Graves'disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study
    Laurberg P [2008]
  • Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy
    Bartalena L [1998]
  • Radioiodine-associated exacerbation of Graves'orbitopathy in the Japanese population: randomized prospective study
    Watanabe N [2015]
  • Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists
    Vaidya B [2008]
  • Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials
    Wang J [2016]
  • Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study
    Peters H [1995]
  • Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome
    Bonnema SJ [2012]
  • Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review
    Acharya SH [2008]
  • Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women
    Goldman MB [1988]
  • Quality-of-life impairments persist six months after treatment of Graves' hyperthyroidism and toxic nodular goiter: a prospective cohort study
    Cramon P [2016]
  • Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study
    Taieb D [2016]
  • Quality of life in patients with Graves ophthalmopathy
    Yeatts RP [2005]
  • Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study
  • Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study
    Okosieme OE [2019]
  • Mortality after the treatment of hyperthyroidism with radioactive iodine
    Franklyn JA [1998]
  • Management of Graves' disease in Australia
    Walsh JP [2000]
  • Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?
    Jarløv AE [1995]
  • Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments
    Terwee CB [2001]
  • Increased cardiovascular mortality and morbidity in patients treated for toxic nodular goiter compared to Graves'disease and nontoxic goiter
    Giesecke P [2017]
  • Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism
    Metso S [2007]
  • Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for Graves' hyperthyroidism: a long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey
    Torring O [2019]
  • Impaired health-related quality of life in Graves' disease. A prospective study
  • Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists
    Bahn RS [2011]
  • High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease
  • Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery
  • Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study
    Brandt F [2013]
  • Current and emerging treatment options for Graves' hyperthyroidism
    Abraham P [2010]
  • Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
    Bartalena L [2008]
  • Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine
    Boelaert K [2013]
  • Clinical and dosimetric variables related to outcome after treatment of Graves' disease with 550and 1110 MBq of 131I: results of a prospective randomized trial
    Sapienza MT [2015]
  • Anxiety and depression are more prevalent in patients with graves' disease than in patients with nodular goitre
    Bove KB [2014]
  • A randomized comparison of radioiodine doses in Graves' hyperthyroidism
    Leslie WD [2003]
  • A 2013European survey of clinical practice patterns in the management of Graves' disease
    Bartalena L [2016]
  • A 2011 survey of clinical practice patterns in the management of Graves' disease
    Burch HB [2012]
  • 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism
    Kahaly GJ [2018]
  • 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis
    Ross DS [2016]